548 related articles for article (PubMed ID: 35292516)
21. Cancer-associated fibroblast-targeted strategy enhances antitumor immune responses in dendritic cell-based vaccine.
Ohshio Y; Teramoto K; Hanaoka J; Tezuka N; Itoh Y; Asai T; Daigo Y; Ogasawara K
Cancer Sci; 2015 Feb; 106(2):134-42. PubMed ID: 25483888
[TBL] [Abstract][Full Text] [Related]
22. PD-L1-Targeted Radionuclide Therapy Combined with αPD-L1 Antibody Immunotherapy Synergistically Improves the Antitumor Effect.
Wen X; Zeng X; Cheng X; Zeng X; Liu J; Zhang Y; Li Y; Chen H; Huang J; Guo Z; Chen X; Zhang X
Mol Pharm; 2022 Oct; 19(10):3612-3622. PubMed ID: 35652897
[TBL] [Abstract][Full Text] [Related]
23. Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma.
Lin X; Zeng T; Xiong J; Zhang Q; Jiang P; Li X; Lin S; Xu Q; Weng H; Lai H; Gong H; Lin J; Cheng N; Tian X; Xu Y; Fang S; Jin R; Chen Z; Yang J; Morton L; Yueh B; Lin J
Cancer Biol Ther; 2019; 20(5):666-679. PubMed ID: 30572778
[TBL] [Abstract][Full Text] [Related]
24. Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations.
Chandramohan V; Bao X; Yu X; Parker S; McDowall C; Yu YR; Healy P; Desjardins A; Gunn MD; Gromeier M; Nair SK; Pastan IH; Bigner DD
J Immunother Cancer; 2019 May; 7(1):142. PubMed ID: 31142380
[TBL] [Abstract][Full Text] [Related]
25. Blockades of effector T cell senescence and exhaustion synergistically enhance antitumor immunity and immunotherapy.
Liu X; Si F; Bagley D; Ma F; Zhang Y; Tao Y; Shaw E; Peng G
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36192086
[TBL] [Abstract][Full Text] [Related]
26. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment.
Fang DD; Tang Q; Kong Y; Wang Q; Gu J; Fang X; Zou P; Rong T; Wang J; Yang D; Zhai Y
J Immunother Cancer; 2019 Nov; 7(1):327. PubMed ID: 31779710
[TBL] [Abstract][Full Text] [Related]
27. Single-Cell Analysis Reveals EP4 as a Target for Restoring T-Cell Infiltration and Sensitizing Prostate Cancer to Immunotherapy.
Peng S; Hu P; Xiao YT; Lu W; Guo D; Hu S; Xie J; Wang M; Yu W; Yang J; Chen H; Zhang X; Zhu Y; Wang Y; Yang Y; Zhu G; Chen S; Wang J; Zhang B; Chen W; Wu H; Sun Z; Ding T; Zhang H; Yi Z; Liu M; Ren S
Clin Cancer Res; 2022 Feb; 28(3):552-567. PubMed ID: 34740924
[TBL] [Abstract][Full Text] [Related]
28. Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses.
Wei J; Montalvo-Ortiz W; Yu L; Krasco A; Ebstein S; Cortez C; Lowy I; Murphy AJ; Sleeman MA; Skokos D
Sci Immunol; 2021 Apr; 6(58):. PubMed ID: 33837124
[TBL] [Abstract][Full Text] [Related]
29. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
30. Tumor Antigen-Primed Dendritic Cell-Derived Exosome Synergizes with Colony Stimulating Factor-1 Receptor Inhibitor by Modulating the Tumor Microenvironment and Systemic Immunity.
Barnwal A; Gaur V; Sengupta A; Tyagi W; Das S; Bhattacharyya J
ACS Biomater Sci Eng; 2023 Nov; 9(11):6409-6424. PubMed ID: 37870457
[TBL] [Abstract][Full Text] [Related]
31. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
32. Overcoming resistance to αPD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of αCTLA-4 and αPD-1 blockers.
Nebot-Bral L; Hollebecque A; Yurchenko AA; de Forceville L; Danjou M; Jouniaux JM; Rosa RCA; Pouvelle C; Aoufouchi S; Vuagnat P; Smolenschi C; Colomba E; Leary A; Marabelle A; Scoazec JY; Cassard L; Nikolaev S; Chaput N; Kannouche P
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35896284
[TBL] [Abstract][Full Text] [Related]
33. Immunomodulation to enhance the efficacy of an HPV therapeutic vaccine.
Smalley Rumfield C; Pellom ST; Morillon Ii YM; Schlom J; Jochems C
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32554612
[TBL] [Abstract][Full Text] [Related]
34. KLF5 inhibition potentiates anti-PD1 efficacy by enhancing CD8
Wu Q; Liu Z; Gao Z; Luo Y; Li F; Yang C; Wang T; Meng X; Chen H; Li J; Kong Y; Dong C; Sun S; Chen C
Theranostics; 2023; 13(4):1381-1400. PubMed ID: 36923542
[No Abstract] [Full Text] [Related]
35. Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1.
Chen J; Yang J; Wang W; Guo D; Zhang C; Wang S; Lu X; Huang X; Wang P; Zhang G; Zhang J; Wang J; Cai Z
Cell Mol Immunol; 2022 Nov; 19(11):1290-1301. PubMed ID: 36220994
[TBL] [Abstract][Full Text] [Related]
36. Red blood cell-based vaccines for ameliorating cancer chemoimmunotherapy.
Su L; Hao Y; Li R; Pan W; Ma X; Weng J; Min Y
Acta Biomater; 2022 Dec; 154():401-411. PubMed ID: 36241013
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer.
Duraiswamy J; Freeman GJ; Coukos G
Cancer Res; 2013 Dec; 73(23):6900-12. PubMed ID: 23975756
[TBL] [Abstract][Full Text] [Related]
38. Decreased melanoma CSF-1 secretion by Cannabigerol treatment reprograms regulatory myeloid cells and reduces tumor progression.
Wyrobnik I; Steinberg M; Gelfand A; Rosenblum R; Eid Mutlak Y; Sulimani L; Procaccia S; Ofran Y; Novak-Kotzer H; Meiri D
Oncoimmunology; 2023; 12(1):2219164. PubMed ID: 37325437
[TBL] [Abstract][Full Text] [Related]
39. Comparing syngeneic and autochthonous models of breast cancer to identify tumor immune components that correlate with response to immunotherapy in breast cancer.
Lal JC; Townsend MG; Mehta AK; Oliwa M; Miller E; Sotayo A; Cheney E; Mittendorf EA; Letai A; Guerriero JL
Breast Cancer Res; 2021 Aug; 23(1):83. PubMed ID: 34353349
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade.
Kwong TT; Wong CH; Zhou JY; Cheng ASL; Sung JJY; Chan AWH; Chan SL
JHEP Rep; 2021 Apr; 3(2):100224. PubMed ID: 33604533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
